XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2017
Sep. 30, 2017
CURRENT ASSETS    
Cash and cash equivalents $ 11,531,345 $ 24,838,567
Accounts receivable 149,931 67,797
Prepaid expenses 651,239 867,363
Other current assets 1,604,986 1,359,638
Short term investments 39,169,376 40,769,539
TOTAL CURRENT ASSETS 53,106,877 67,902,904
Property and equipment, net 14,932,366 15,513,019
Intangible assets, net 20,039,332 20,464,439
Other assets 141,918 141,918
TOTAL ASSETS 88,220,493 104,022,280
CURRENT LIABILITIES    
Accounts payable 5,707,047 4,076,514
Accrued expenses 3,478,512 4,564,507
Accrued payroll and benefits 1,936,024 3,399,679
Deferred rent 440,580 440,580
Deferred revenue 1,875,001 5,269,741
Derivative liabilities 20,445 695,114
Note Payable 212,233 208,506
Other current liabilities 46,407 46,407
TOTAL CURRENT LIABILITIES 13,716,249 18,701,048
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 1,834,392 1,929,052
Note Payable, net of current portion 2,270,542 2,325,018
Other non-current liabilities 200,000 200,000
TOTAL LONG-TERM LIABILITIES 4,304,934 4,454,070
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:    
Common stock, $0.001 par value; 145,000,000 shares authorized; 74,917,876 and 74,785,426 shares issued and outstanding as of December 31, 2017 and September 30, 2017, respectively 167,287 167,155
Additional paid-in capital 516,577,723 514,037,301
Accumulated other comprehensive income (loss) 23,704 33,232
Accumulated deficit (446,014,216) (432,815,338)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 70,754,498 81,422,350
Noncontrolling interest (555,188) (555,188)
TOTAL STOCKHOLDERS’ EQUITY 70,199,310 80,867,162
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 88,220,493 $ 104,022,280